These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 30409750)
1. Co-delivery of siRNA and etoposide to cancer cells using an MDEA esterquat based drug delivery system. Popova P; Notabi MK; Code C; Arnspang EC; Andersen MØ Eur J Pharm Sci; 2019 Jan; 127():142-150. PubMed ID: 30409750 [TBL] [Abstract][Full Text] [Related]
2. Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor. Yuan ZQ; Chen WL; You BG; Liu Y; Yang SD; Li JZ; Zhu WJ; Zhou XF; Liu C; Zhang XN J Control Release; 2017 Dec; 268():198-211. PubMed ID: 29061511 [TBL] [Abstract][Full Text] [Related]
3. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765 [TBL] [Abstract][Full Text] [Related]
4. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601 [TBL] [Abstract][Full Text] [Related]
5. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968 [TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Xiao B; Ma L; Merlin D Expert Opin Drug Deliv; 2017 Jan; 14(1):65-73. PubMed ID: 27337289 [TBL] [Abstract][Full Text] [Related]
7. Nanoformulation of siRNA silencing Bcl-2 gene and its implication in cancer therapy. Jagani HV; Josyula VR; Hariharapura RC; Palanimuthu VR; Gang SS Arzneimittelforschung; 2011; 61(10):577-86. PubMed ID: 22164966 [TBL] [Abstract][Full Text] [Related]
8. Liposomal co-delivery-based quantitative evaluation of chemosensitivity enhancement in breast cancer stem cells by knockdown of GRP78/CLU. Samson AAS; Park S; Kim SY; Min DH; Jeon NL; Song JM J Liposome Res; 2019 Mar; 29(1):44-52. PubMed ID: 29262741 [TBL] [Abstract][Full Text] [Related]
9. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy. Lee SY; Yang CY; Peng CL; Wei MF; Chen KC; Yao CJ; Shieh MJ Biomaterials; 2016 Apr; 86():92-105. PubMed ID: 26896610 [TBL] [Abstract][Full Text] [Related]
10. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Yadav S; van Vlerken LE; Little SR; Amiji MM Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115 [TBL] [Abstract][Full Text] [Related]
11. Enhanced cellular uptake and gene silencing activity of siRNA using temperature-responsive polymer-modified liposome. Wang J; Ayano E; Maitani Y; Kanazawa H Int J Pharm; 2017 May; 523(1):217-228. PubMed ID: 28330734 [TBL] [Abstract][Full Text] [Related]
12. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631 [TBL] [Abstract][Full Text] [Related]
13. Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach. Thanki K; Zeng X; Justesen S; Tejlmann S; Falkenberg E; Van Driessche E; Mørck Nielsen H; Franzyk H; Foged C Eur J Pharm Biopharm; 2017 Nov; 120():22-33. PubMed ID: 28756280 [TBL] [Abstract][Full Text] [Related]
14. Co-delivery of chemosensitizing siRNA and an anticancer agent via multiple monocomplexation-induced hydrophobic association. Lee E; Oh C; Kim IS; Kwon IC; Kim S J Control Release; 2015 Jul; 210():105-14. PubMed ID: 25979325 [TBL] [Abstract][Full Text] [Related]
15. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. Varshosaz J; Farzan M World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089 [TBL] [Abstract][Full Text] [Related]
16. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848 [TBL] [Abstract][Full Text] [Related]
17. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. Jang YL; Yun UJ; Lee MS; Kim MG; Son S; Lee K; Chae SY; Lim DW; Kim HT; Kim SH; Jeong JH Int J Pharm; 2012 Sep; 434(1-2):488-93. PubMed ID: 22613208 [TBL] [Abstract][Full Text] [Related]
18. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. Jensen DK; Jensen LB; Koocheki S; Bengtson L; Cun D; Nielsen HM; Foged C J Control Release; 2012 Jan; 157(1):141-8. PubMed ID: 21864597 [TBL] [Abstract][Full Text] [Related]
19. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Spagnou S; Miller AD; Keller M Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141 [TBL] [Abstract][Full Text] [Related]
20. Tumoral gene silencing by receptor-targeted combinatorial siRNA polyplexes. Lee DJ; He D; Kessel E; Padari K; Kempter S; Lächelt U; Rädler JO; Pooga M; Wagner E J Control Release; 2016 Dec; 244(Pt B):280-291. PubMed ID: 27287890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]